Trial Profile

Intranasal Human Abuse Liability (HAL) study to compare the opioid abuse potential after a single dose of hydrocodone extended-release tablet (crushed) versus intranasal hydrocodone powder

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Feb 2015 According to a Teva Pharmaceutical Industries media release, the US FDA has accepted for review an NDA supported in part by results of this study and another study investigating the abuse potential of CEP 33237.
07 Nov 2014 New trial record
08 Oct 2014 Data from this study will support the NDA submission to the US FDA which is expected to be completed by the end of 2014, according to a Teva Pharmaceutical Industries media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com